Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2022-01-03 Report Publication Anno…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH annonce sa participation en janvier à des conférences investisseurs virtuelles
Report Publication Announcement Classification · 1% confidence The document is a press release from ERYTECH Pharma dated January 3, 2022, announcing its participation in upcoming investor conferences in January 2022 (LifeSci Partners and H.C. Wainwright BioConnect). It details the dates and provides information on how to schedule one-on-one meetings or access webcasts related to these events. This type of announcement, which informs investors about scheduled participation in external investor relations events (conferences, roadshows), fits best under the category of Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement related to investor engagement. Since the core purpose is announcing participation in investor conferences and offering one-on-one meetings, it is a communication aimed at investors regarding future engagement opportunities. While it is not a formal regulatory filing, it is a specific type of investor communication. Given the options, 'Investor Presentation' (IP) is often used broadly for investor-facing materials, but this is an announcement *about* presentations/meetings. However, the content is primarily about scheduling investor engagement, which is a key component of investor relations activities. Since there isn't a specific 'Investor Conference Announcement' code, and the document is not a formal report (10-K, IR) or a simple dividend/share change notice, we must choose the closest fit. It is an announcement designed to facilitate investor interaction, similar in spirit to an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the focus on specific investor conferences and meetings, 'Investor Presentation' (IP) is the most relevant category for proactive investor outreach materials, even though this is an announcement *of* the outreach rather than the presentation slides themselves. If the document were purely a notice that a report was published, RPA would apply, but this is about future events. I will classify it as Investor Presentation (IP) as it pertains directly to scheduled investor engagement events.
2022-01-03 French
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
Regulatory Filings Classification · 1% confidence The document is a press release dated January 3, 2022, announcing that ERYTECH Pharma will participate in upcoming investor conferences (LifeSci Partners and H.C. Wainwright BioConnect) and will be available for one-on-one meetings. This type of announcement, which details participation in investor events and roadshows, is best classified as an Investor Presentation (IP) or related communication, as it is designed to engage investors about the company's status and pipeline. However, none of the definitions perfectly match 'Investor Conference Participation Announcement'. Reviewing the definitions: - ER (Earnings Release): No financial results are announced. - CT (Call Transcript): This is not a transcript. - IP (Investor Presentation): While it relates to investor engagement, it is an announcement *about* attending events, not the presentation material itself. - RPA (Report Publication Announcement): This is not announcing the publication of a formal financial report (like 10-K or IR). Given the context of a clinical-stage biopharma company actively engaging investors by announcing conference participation and one-on-one meetings, this falls under general investor relations communication. Since there is no specific code for 'Investor Conference Announcement', the closest fit among the provided options that relates to proactive investor engagement and presentation of company status (which often accompanies these events) is 'Investor Presentation' (IP), or potentially 'Regulatory Filings' (RNS) as a general catch-all. However, since the core purpose is to inform investors about upcoming engagement opportunities, 'IP' is the most contextually relevant choice among the specific options, even if it's an announcement *of* engagement rather than the presentation itself. If the document were purely a notice about a future report release, RPA would fit, but this is about conference attendance and meetings. Considering the options, and recognizing this is a standard type of communication used to promote investor interest, I will classify it as Investor Presentation (IP), as these announcements often serve as a precursor or summary of the information that would be presented in the actual meetings/webcasts.
2022-01-03 English
Franchissement de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclarations de franchissements de seuils (article L. 233-7 du code de commerce)" and details changes in share ownership thresholds crossed by The Goldman Sachs Group, Inc. in ERYTECH PHARMA. This type of filing, reporting changes in significant share ownership (crossing thresholds), directly corresponds to the definition of Major Shareholding Notification (MRQ). The content explicitly discusses holdings crossing the 5% threshold, which is the core function of an MRQ filing.
2021-12-28 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing in France specifically reports when an investor's stake in a listed company crosses statutory ownership thresholds (like 5%, 10%, etc.). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant share ownership levels crossing thresholds. The filing explicitly mentions the crossing of the 5% threshold by Armistice Capital, LLC. Therefore, the appropriate code is MRQ (Major Shareholding Notification).
2021-12-24 French
ERYTECH annonce la levée de 7,85 millions de dollars dans le cadre d’une Registered Offering
Capital/Financing Update Classification · 1% confidence The document is a press release from ERYTECH Pharma dated December 14, 2021, announcing the conclusion of a definitive agreement for a financing round. Key phrases include 'annonce la levée de 7,85 millions de dollars dans le cadre d'une Registered Offering', 'souscription de 769 608 actions assorties de bons de souscription d'actions', and details about the capital increase, pricing, and use of proceeds. This clearly describes a capital raising or financing activity. This aligns directly with the definition for 'Capital/Financing Update' (CAP). Although it mentions SEC filings (Form F-3) and AMF filings (Prospectus/URD amendments), the primary purpose of this specific document is to announce the financing transaction itself, not to be the final regulatory report (like a 10-K or IR) or merely an announcement of a report's publication (RPA/RNS).
2021-12-14 French
ERYTECH Announces $7.85 Million Registered Direct Offering
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a registered direct offering of securities (shares and warrants) by ERYTECH Pharma. It details the terms of the capital increase, the use of proceeds, and the regulatory filings associated with the offering. This falls under the category of capital and financing updates, as it describes a specific fundraising event and its impact on the company's capital structure.
2021-12-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.